 | • レポートコード：MRC23Q35832 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の血液腫瘍薬市場について調査・分析し、世界の血液腫瘍薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（化学療法、標的療法、免疫療法、その他）、用途別セグメント分析（白血病、リンパ腫、多発性骨髄腫、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bristol-Myers Squibb、Johnson & Johnson、AbbVie、Novartis、Roche、Amgen、Takeda、Pfizer、AstraZeneca、Gilead Sciencesなどが含まれています。世界の血液腫瘍薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、血液腫瘍薬市場規模を推定する際に考慮しました。本レポートは、血液腫瘍薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、血液腫瘍薬に関するビジネス上の意思決定に役立てることを目的としています。 ・血液腫瘍薬市場の概要 - 血液腫瘍薬のタイプ別セグメント - 世界の血液腫瘍薬市場規模：タイプ別分析（化学療法、標的療法、免疫療法、その他） - 血液腫瘍薬の用途別セグメント - 世界の血液腫瘍薬市場規模：用途別分析（白血病、リンパ腫、多発性骨髄腫、その他） - 世界の血液腫瘍薬市場規模予測（2018年-2029年） ・血液腫瘍薬市場の成長トレンド - 血液腫瘍薬の地域別市場規模（2018年-2029年） - 血液腫瘍薬市場ダイナミクス - 血液腫瘍薬の業界動向 - 血液腫瘍薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：化学療法、標的療法、免疫療法、その他 - 世界の血液腫瘍薬のタイプ別市場規模（2018年-2023年） - 世界の血液腫瘍薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：白血病、リンパ腫、多発性骨髄腫、その他 - 世界の血液腫瘍薬の用途別市場規模（2018年-2023年） - 世界の血液腫瘍薬の用途別市場規模（2024年-2029年） ・血液腫瘍薬の地域別市場規模 - 北米の血液腫瘍薬市場規模（2018年-2029年） - アメリカの血液腫瘍薬市場規模（2018年-2029年） - ヨーロッパの血液腫瘍薬市場規模（2018年-2029年） - アジア太平洋の血液腫瘍薬市場規模（2018年-2029年） - 中国の血液腫瘍薬市場規模（2018年-2029年） - 日本の血液腫瘍薬市場規模（2018年-2029年） - 韓国の血液腫瘍薬市場規模（2018年-2029年） - インドの血液腫瘍薬市場規模（2018年-2029年） - オーストラリアの血液腫瘍薬市場規模（2018年-2029年） - 中南米の血液腫瘍薬市場規模（2018年-2029年） - 中東・アフリカの血液腫瘍薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bristol-Myers Squibb、Johnson & Johnson、AbbVie、Novartis、Roche、Amgen、Takeda、Pfizer、AstraZeneca、Gilead Sciences ・アナリストの観点/結論 ・調査方法とデータソース |
Blood Tumor, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.
Highlights
The global Blood Tumor Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Blood Tumor Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Blood Tumor Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Blood Tumor Drugs in Leukemia is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Blood Tumor Drugs include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer and AstraZeneca, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Blood Tumor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Tumor Drugs.
The Blood Tumor Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Blood Tumor Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Tumor Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Other
Segment by Application
Leukemia
Lymphoma
Multiple Myeloma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Tumor Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Tumor Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Blood Tumor Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Multiple Myeloma
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Tumor Drugs Market Perspective (2018-2029)
2.2 Blood Tumor Drugs Growth Trends by Region
2.2.1 Global Blood Tumor Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Blood Tumor Drugs Historic Market Size by Region (2018-2023)
2.2.3 Blood Tumor Drugs Forecasted Market Size by Region (2024-2029)
2.3 Blood Tumor Drugs Market Dynamics
2.3.1 Blood Tumor Drugs Industry Trends
2.3.2 Blood Tumor Drugs Market Drivers
2.3.3 Blood Tumor Drugs Market Challenges
2.3.4 Blood Tumor Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Tumor Drugs Players by Revenue
3.1.1 Global Top Blood Tumor Drugs Players by Revenue (2018-2023)
3.1.2 Global Blood Tumor Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Blood Tumor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Blood Tumor Drugs Revenue
3.4 Global Blood Tumor Drugs Market Concentration Ratio
3.4.1 Global Blood Tumor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Tumor Drugs Revenue in 2022
3.5 Blood Tumor Drugs Key Players Head office and Area Served
3.6 Key Players Blood Tumor Drugs Product Solution and Service
3.7 Date of Enter into Blood Tumor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Tumor Drugs Breakdown Data by Type
4.1 Global Blood Tumor Drugs Historic Market Size by Type (2018-2023)
4.2 Global Blood Tumor Drugs Forecasted Market Size by Type (2024-2029)
5 Blood Tumor Drugs Breakdown Data by Application
5.1 Global Blood Tumor Drugs Historic Market Size by Application (2018-2023)
5.2 Global Blood Tumor Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Blood Tumor Drugs Market Size (2018-2029)
6.2 North America Blood Tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Blood Tumor Drugs Market Size by Country (2018-2023)
6.4 North America Blood Tumor Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Tumor Drugs Market Size (2018-2029)
7.2 Europe Blood Tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Blood Tumor Drugs Market Size by Country (2018-2023)
7.4 Europe Blood Tumor Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Tumor Drugs Market Size (2018-2029)
8.2 Asia-Pacific Blood Tumor Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Blood Tumor Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Blood Tumor Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Tumor Drugs Market Size (2018-2029)
9.2 Latin America Blood Tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Blood Tumor Drugs Market Size by Country (2018-2023)
9.4 Latin America Blood Tumor Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Tumor Drugs Market Size (2018-2029)
10.2 Middle East & Africa Blood Tumor Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Blood Tumor Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Blood Tumor Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Blood Tumor Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Blood Tumor Drugs Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Blood Tumor Drugs Introduction
11.2.4 Johnson & Johnson Revenue in Blood Tumor Drugs Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Blood Tumor Drugs Introduction
11.3.4 AbbVie Revenue in Blood Tumor Drugs Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Blood Tumor Drugs Introduction
11.4.4 Novartis Revenue in Blood Tumor Drugs Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Blood Tumor Drugs Introduction
11.5.4 Roche Revenue in Blood Tumor Drugs Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Blood Tumor Drugs Introduction
11.6.4 Amgen Revenue in Blood Tumor Drugs Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Takeda
11.7.1 Takeda Company Detail
11.7.2 Takeda Business Overview
11.7.3 Takeda Blood Tumor Drugs Introduction
11.7.4 Takeda Revenue in Blood Tumor Drugs Business (2018-2023)
11.7.5 Takeda Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Blood Tumor Drugs Introduction
11.8.4 Pfizer Revenue in Blood Tumor Drugs Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Blood Tumor Drugs Introduction
11.9.4 AstraZeneca Revenue in Blood Tumor Drugs Business (2018-2023)
11.9.5 AstraZeneca Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Detail
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Blood Tumor Drugs Introduction
11.10.4 Gilead Sciences Revenue in Blood Tumor Drugs Business (2018-2023)
11.10.5 Gilead Sciences Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details